中文版
  • Company news


Oceanpine Theme Seminar ——“The status and development of the pharmaceutical industry” was successfully held in Beijing

May 10, 2021

on April 18th ,The Oceanpine Capital Investment Salon —— "The Current Status and Development of the Pharmaceutical Industry" was successfully held in Beijing...

Investee Company:Hepagene Therapeutics Inc. nets $40m in Series B1

Apr 26, 2021

Clinical stage drug discovery and development firm Hepagene Therapeutics Inc. on Tuesday said it has garnered a total of $40 million in its Series B1 round led by ByteDance-backer Loyal Valley Capital. Oceanpine Capital...

The 1st Oceanpine Capital Investment Salon in 2021 was successfully held in Beijing

Apr 23, 2021

On April 23, Oceanpine Capital's first salon of this year—— Digital Industry and New Retail Strategy Transformation was successfully held in China Century Building...

Investee Company:Horizon Robotics signed a strategic cooperation agreement with WILLSEMI and received strategic investment

Apr 22, 2021

On April 22, the investee company of Oceanpine Capital —— Horizon Robotics signed a strategic cooperation agreement with WILLSEMI and announced that it had received strategic investment from Weihao Chuangxin...

Investee Company:EdiGene Raises RMB 400 million in Series B Plus Financing

Apr 21, 2021

Apr. 21, 2021 -- EdiGene, Inc. ("Company", or "EdiGene"), today announced the successful completion of an RMB 400 million (approximately USD 62 million) Series B Plus financing...

Investee Company: TechnoDerma announced the completion of Series A financing

Apr 07, 2021

Technoderma is a leader in the research and development of innovative drugs for skin indications. The success of this round of financing provides a strong support to the company to rapidly advance the preclinical research and IND filing of its drug R&D pi

Investee Company:Immune-Onc Therapeutics Announces $73 Million in Series B1 and B2 Financing

Mar 31, 2021

Proceeds will support development of novel myeloid checkpoint inhibitors including its clinical program IO-202, a first-in-class LILRB4 antagonist antibody in blood cancers and solid tumors, and its preclinical programs IO-108 and IO-106...

Investee Company: FlashEx Secures USD 125 Million in Series D2 Round

Mar 30, 2021

On March 30, FlashEx, a provider of short-distance and same-city logistics services, said on Tuesday that it has raked in $125 million in a Series D2 round fund...

Investee Company:Zhihu Lists on New York Stock Exchange

Mar 26, 2021

Oceanpine Capital Investee company——Zhihu (NYSE: ZH) on March 26th EST listed on the New York Stock Exchange. The issue price is US$9.5/ADS...

Dave Chenn visited BOE Technology Group to conduct strategic cooperation and exchanges around industrial resources

Mar 12, 2021

On March 11, 2021, Mr. Dave Chenn, CEO and Managing Partner of Oceanpine Capital, led the company's executives to visit BOE Technology, had a cordial talk with Xiaodong Liu ,Chairman of BOE and other group executives...
123456